Weighing Tumor Biology in Treatment Decisions for Patients with Non-small Cell Lung Cancer
Open Access
- 1 June 2007
- journal article
- review article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 2 (6), S68-S76
- https://doi.org/10.1097/01.jto.0000269737.05962.a0
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- EGFR and erbB2 mutation status in Japanese lung cancer patientsInternational Journal of Cancer, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Association of HER‐2 overexpression with prognosis in nonsmall cell lung carcinoma: A metaanalysisCancer, 2005
- KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2005
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Trimodality treatment in Stage III nonsmall cell lung carcinomaCancer, 2002
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.JCI Insight, 1997